CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study
- PMID: 19222507
- DOI: 10.1111/j.1399-0012.2009.00976.x
CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study
Abstract
Background: Cytomegalovirus (CMV) infection is still the leading opportunistic infection following solid organ transplantation. The aim of this prospective study of renal transplant recipients was to evaluate the dynamics of CMV-specific T-cells, viral load, and clinical symptoms of CMV infection.
Methods: Levels of tetramer-selected CD8(+) T-cells (TetraCD8), CMV-specific interferon-gamma producing CD8(+) T-cells (IFNgammaCD8), and CD4(+) T-cells (IFNgammaCD4), measured using major histocompatibility complex-tetramer and cytokine flow cytometry techniques, and CMV DNA were monitored monthly in 17 CMV-seropositive patients up to one yr (median 12 months, range 3-12) after transplantation and correlated to clinical outcome.
Results: CMV DNAemia was detected in 94% of the patients, but only one patient developed CMV disease. CMV DNAemia >1 million copies/mL was seen in asymptomatic patients. CMV-specific T-cells decreased rapidly after transplantation. TetraCD8 and IFNgammaCD8 regenerated within three months, whereas IFNgammaCD4 recovery was impaired up to one yr after transplantation. The proportion of IFNgammaCD4 at two months post-transplantation as compared with baseline, correlated strongly with the magnitude of the CMV DNAemia.
Conclusions: Monitoring the reduction of IFNgammaCD4 compared with baseline during the first months after transplantation could be considered in predicting risk for high-grade CMV DNAemia and in deciding strategic approaches for pre-emptive and prophylactic therapy.
Similar articles
-
A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection.Transpl Int. 2010 May 1;23(5):506-13. doi: 10.1111/j.1432-2277.2009.01017.x. Epub 2009 Nov 27. Transpl Int. 2010. PMID: 19951371
-
Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.Haematologica. 2008 Feb;93(2):248-56. doi: 10.3324/haematol.11912. Haematologica. 2008. PMID: 18245650
-
Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.J Med Virol. 2010 Jul;82(7):1208-15. doi: 10.1002/jmv.21799. J Med Virol. 2010. PMID: 20513086
-
Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants.Biol Blood Marrow Transplant. 2004 Jul;10(7):433-47. doi: 10.1016/j.bbmt.2003.12.004. Biol Blood Marrow Transplant. 2004. PMID: 15205665 Review.
-
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician.Clin Infect Dis. 2012 Dec;55(12):1678-89. doi: 10.1093/cid/cis818. Epub 2012 Sep 18. Clin Infect Dis. 2012. PMID: 22990848 Review.
Cited by
-
CMV-specific immune reconstitution following allogeneic stem cell transplantation.Virulence. 2016 Nov 16;7(8):967-980. doi: 10.1080/21505594.2016.1221022. Epub 2016 Aug 9. Virulence. 2016. PMID: 27580355 Free PMC article. Review.
-
CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.PLoS Pathog. 2011 Nov;7(11):e1002367. doi: 10.1371/journal.ppat.1002367. Epub 2011 Nov 10. PLoS Pathog. 2011. PMID: 22102814 Free PMC article.
-
Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation.J Clin Microbiol. 2022 Aug 17;60(8):e0171621. doi: 10.1128/jcm.01716-21. Epub 2022 May 11. J Clin Microbiol. 2022. PMID: 35543099 Free PMC article. Review.
-
Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies.Infect Chemother. 2017 Sep;49(3):161-175. doi: 10.3947/ic.2017.49.3.161. Infect Chemother. 2017. PMID: 29027383 Free PMC article. Review.
-
Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?Transpl Int. 2023 Nov 7;36:11963. doi: 10.3389/ti.2023.11963. eCollection 2023. Transpl Int. 2023. PMID: 38020746 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials